Calendrier des promotions NuCana plc
Calendrier avancé
Graphique simple
À propos de l'entreprise NuCana plc
NuCana plc, биофармацевтическая компания, работающая на клинической стадии, занимается разработкой продуктов для лечения рака. Компания разрабатывает свои продукты на основе собственной технологии ProTide. plus de détailsParamètres de base
IPO date
2017-09-28
ISIN
US67022C1062
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
gbp
Див.доход ао
0
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 0 | 0 |
| P/BV | 18.51 | 1 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -89.22 | 0 |
| ROE | -182.3 | 0 |
| ROIC | -49 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | -0.0066 | 10 |
| Debt/Ratio | 0.0129 | 10 |
| Debt/Equity | 1.48 | 8 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 0 | 0 |
| Rentabilité Ebitda, % | 20.66 | 4 |
| Rentabilité EPS, % | -99.75 | 0 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 0.038 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 0.0482 $ | 0 $ | 0 $ | -21.16 % | 0 % | 0 % |
| common.calendar.number_days.30d | 0.65 $ | 0.0329 $ | 0.0534 $ | -94.15 % | 0 % | 0 % |
| common.calendar.number_days.90d | 1.02 $ | 0.0329 $ | 1.28 $ | -96.27 % | 0 % | 0 % |
| common.calendar.number_days.180d | 1.33 $ | 0.0329 $ | 1.42 $ | -97.14 % | 0 % | 0 % |
| common.calendar.number_days.1y | 3.52 $ | 0.0329 $ | 9.7 $ | -98.92 % | 0 % | 0 % |
| common.calendar.number_days.3y | 0.6728 $ | 0.0329 $ | 10.5 $ | -94.35 % | 0 % | 0 % |
| common.calendar.number_days.5y | 6.27 $ | 0.0329 $ | 10.5 $ | -99.39 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0 $ | 0.0329 $ | 29.84 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 1.27 $ | 0.0329 $ | 1.31 $ | -97 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Mr. Hugh Stephen Griffith | Founder, CEO & Executive Director | 1.23M | 1968 (57 années) |
| Mr. Donald Munoz | Chief Financial Officer | N/A | 1969 (56 années) |
| Mr. David Harrison | Head of Translational Medicine | 1960 (65 années) | |
| Dr. Jeffrey D. Bloss F.A.C.O.G., M.D. | Chief Medical Officer | 1958 (67 années) | |
| Ms. Theresa Bruce | Senior Vice President of Clinical Operations | ||
| Ms. Elisabeth Oelmann | Senior Vice President of Medical & Clinical Development | ||
| Mr. John-Paul Gallivan | Senior VP of Strategy & Lifecycle Management | ||
| Mr. Gordon Kennovin | Senior VP of CMC & Development | ||
| Dr. Stuart Grant | Senior Vice President of Regulatory Affairs | ||
| Martin Quinn | Company Secretary |
Informations sur l'entreprise
Adresse: United Kingdom, Edinburgh, 3 Lochside Way - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.nucana.com
Site web: https://www.nucana.com
